Erasmus Medical Centre
Loss of lenalidomide-induced megakaryocytic differentiation leads to therapy resistance in del(5q) myelodysplastic syndrome
May 14, 2020
My research interests lie in the development of effective treatments for hematological malignancies. My goal is to apply the research in the molecular mechanisms of anti-tumor activity and tumor therapy resistance to the rational design of novel and more effective treatments. My recent work focused on the molecular mechanisms leading to resistance to lenalidomide in myelodysplastic syndromes with deletion in the 5q chromosome.
Keywords
hematopoiesis, myeloid malignancies, drug resistance, lenalidomide
Blood and Bone Seminar 